Premium
HbA 1c in adults without known diabetes from southern Europe. Impact of the new diagnostic criteria in clinical practice
Author(s) -
BernalLopez M. R.,
SantamaríaFernandez S.,
LopezCarmona D.,
Tinahones F. J.,
ManceraRomero J.,
PeñaJimenez D.,
JansenChaparro S.,
BacaOsorio A. J.,
CuestaMuñoz A. L.,
SerranoRios M.,
GomezHuelgas R.
Publication year - 2011
Publication title -
diabetic medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.474
H-Index - 145
eISSN - 1464-5491
pISSN - 0742-3071
DOI - 10.1111/j.1464-5491.2011.03317.x
Subject(s) - medicine , diabetes mellitus , plasma glucose , impaired fasting glucose , population , type 2 diabetes , endocrinology , impaired glucose tolerance , gastroenterology , environmental health
Diabet. Med. 28, 1319–1322 (2011) Abstract Aims To analyse the differences in the prevalence of diabetes and dysglycaemia using fasting plasma glucose and HbA 1c criteria. Methods Analytical cross‐sectional study undertaken in a random sample of 2144 individuals (age 18–80 years) without known diabetes from the primary care setting in Malaga (Spain). Dysglycaemia was defined as fasting plasma glucose 5.6–6.9 mmol/l or HbA 1c 39–46 mmol/mol (5.7–6.4%) and diabetes as fasting plasma glucose ≥ 7.0 mmol/l or HbA 1c ≥ 48 mmol/mol (≥ 6.5%). Results The proportion of subjects who were normoglycaemic was significantly higher using fasting plasma glucose than HbA 1c (83.5 vs. 65%) ( P < 0.0001). Compared with fasting plasma glucose, HbA 1c detects more cases of dysglycaemia (32 vs. 14.8%) ( P < 0.0001) and diabetes (3 vs. 1.7%) ( P < 0.0001). Conclusions In our environment, using HbA 1c for the diagnosis of pre‐diabetes and diabetes could increase the target population for preventive and therapeutic measures. Further cost‐effectiveness studies are needed before the widespread diagnostic use of HbA 1c can be recommended.